BONE;
DRUG THERAPY;
MASS SPECTROMETERS;
PHARMACOKINETICS;
TOXICITY;
TRANSPLANTATION (SURGICAL);
PLASMA;
LIQUID CHROMATOGRAPHY;
BUSULFAN;
ANALYTIC METHOD;
ARTICLE;
BONE MARROW TRANSPLANTATION;
CHILD;
CLINICAL ARTICLE;
CONTROLLED STUDY;
DRUG BLOOD LEVEL;
DRUG CLEARANCE;
DRUG DETERMINATION;
DRUG STRUCTURE;
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;
HUMAN;
INTERMETHOD COMPARISON;
MASS SPECTROMETRY;
PRIORITY JOURNAL;
SENSITIVITY AND SPECIFICITY;
VALIDATION PROCESS;
ADMINISTRATION, ORAL;
ANTINEOPLASTIC AGENTS, ALKYLATING;
BUSULFAN;
CHILD;
CHILD, PRESCHOOL;
CHROMATOGRAPHY, HIGH PRESSURE LIQUID;
HUMANS;
INFANT;
MASS SPECTROMETRY;
REFERENCE STANDARDS;
REPRODUCIBILITY OF RESULTS;
SENSITIVITY AND SPECIFICITY;